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Abstract
Background: Transforming growth factor (TGF)-b signaling pathway, may act both as a tumor suppressor and as a tumor
promoter in pancreatic cancer, depending on tumor stage and cellular context. TGF-b pathway has been under intensive
investigation as a potential therapeutic target in the treatment of cancer. We hypothesized a correlation between TGF-bR2/
SMAD4 expression in the tumor, plasma TGF-b1 ligand level, genetic variation in TGF-B pathway and prognosis of pancreatic
cancer.
Method: We examined TGF-bR2 and SMAD4 protein expression in biopsy or surgical samples from 91 patients with
pancreatic ductal adenocarcinoma (PDAC) using immunohistochemistry. Plasma level of TGF-b1 was measured in 644
patients with PDAC using ELISA. Twenty-eight single nucleotide polymorphisms (SNP) of the TGF-b1, TGF-b2, TGF-b3, TGF-
bR1, TGF-bR2, and SMAD4 genes were determined in 1636 patients with PDAC using the Sequenom method. Correlation
between protein expression in the tumor, plasma TGF-b1 level, and genotypes with overall survival (OS) was evaluated with
Cox proportional regression models.
Results: The expression level of TGF-bR2 and SMAD4 as an independent marker was not associated with OS. However,
patients with both low nuclear staining of TGF-bR2 and high nuclear staining of SMAD4 may have better survival (P= 0.06).
The mean and median level of TGF-b1 was 15.44 (SD: 10.99) and 12.61 (interquartile range: 8.31 to 19.04) ng/ml respectively.
Patients with advanced disease and in the upper quartile range of TGF-b1 level had significantly reduced survival than those
with low levels (P= 0.02). A significant association of SMAD4 SNP rs113545983 with overall survival was observed
(P,0.0001).
Conclusion: Our data provides valuable baseline information regarding the TGF-b pathway in pancreatic cancer, which can
be utilized in targeted therapy clinical trials. High TGF-b1 plasma level, SMAD4 SNP or TGF-bR2/SMAD4 tumor protein
expression may suggest a dependence on this pathway in patients with advanced pancreatic cancer.
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Introduction
Transforming growth factor-b (TGF-b) plays a vital role in cell
cycle arrest, apoptosis, homeostasis, wound healing and immune
regulation. In the case of cancers, TGF-b signaling plays a context-
dependent dual role, both as a tumor suppressor in early stage
disease and as a tumor promoter in established cancers [1]. There
are three TGF-b isoforms, TGF-b1, 2 and 3. Of these, TGF-b1 is
the most abundant in humans. TGF-b signaling occurs at several
stages, starting with activation and release of the TGF-b1 followed
by binding to three high affinity receptors (TGF-bR1, 2 and 3).
TGF-bR1 and TGF-bR2 receptors dimerize after binding TGF-b
at the cell surface [2]. These receptors, when sequentially activated
phosphorylate a family of transcription factors, the SMADs. A
recent exome sequencing study indicated that TGF-bR2 is one of
the 16 most commonly mutated genes in pancreatic cancer [3].
SMAD2 and SMAD3 are activated by TGF-bR1 and bind to the
common partner SMAD4. SMAD6 and SMAD7 are inhibitory
SMADs that block the phosphorylation of SMAD2 or SMAD3.
The activated SMAD complex upon translocation to the nucleus
regulates the transcription of several TGF-b-dependent genes that
may have a context-dependent, tumor-suppressive or progressive
role. Besides this ‘canonical’ TGF-b signaling pathway, there exist
a variety of intracellular signaling pathways that are activated by
TGF-b independently of SMAD2 or SMAD3 activation [4]. TGF-
b signaling is activated in several known human cancers and is
therefore an area of active investigation [5].
TGF-b pathway is one of the 12 core signaling pathways
involved in pancreatic cancer [6]. Mutation in at least one of the
TGF-b pathway genes occurs in 100% of the pancreatic tumors.
LOH at 18q where SMAD4 gene is located occurs in 90% of
pancreatic cancers while gene deletions and loss of protein
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expression occur in 50% [7,8]. Loss of SMAD4 (DPC4) has been
used to determine pancreatic origin in cases of metastases of
unknown primary. It is believed that compromised TGF-b
signaling may account for tumor progression rather than its
initiation [4]. However, the actual role of SMAD4 in pancreatic
cancer is still regarded as controversial. For instance, Biankin et al
demonstrated that SMAD4 expression accounted for a worse
prognosis in case of surgically resectable disease; patients with
SMAD4 overexpression did not benefit from surgical resection in
their study [9]. On the other hand, rapid autopsy data suggest that
SMAD4 loss is associated with disseminated disease [10]. There
are limited data regarding TGF-b receptor and SMAD4
expression or their prognostic significance in advanced pancreatic
cancer patients. Furthermore, there are no data regarding TGF-
b1 plasma level in pancreatic cancer and its correlation with
prognosis.
Genetic variations of the TGF-b pathway genes have been
reported in breast, ovarian, colon, non-small cell lung and colon
cancers and may predict cancer susceptibility or have prognostic
significance [11–15]. However, there are no data to our
knowledge in regards to the same in pancreatic cancer. We
hypothesize that TGF-b pathway activation is common in
pancreatic cancer and genetic variations of the pathway, plasma
TGF-b1 level and tumor TGF-bR2 or SMAD4 expression are
associated with clinical outcome of pancreatic cancer. The
identification of a cohort pancreatic cancer cases wherein the
pathway is activated could potentially lead to patient selection for
TGF-b-targeted therapy.
Methods
Patient Population and Biospecimens
All patients with pathologically confirmed pancreatic ductal
adenocarcinoma (PDAC) and who signed an informed consent for
medical record review and correlative studies for research were
included. The Institutional Review Board of MD Anderson
Cancer Center approved the study. Clinical information on date of
patient diagnosis, date of death or last follow-up, tumor resection
status, clinical tumor stage, and level of serum carbohydrate
antigen 19–9 (CA19-9) at diagnosis was retrieved from patients
medical records. Tissue samples, plasma and tumor DNA were
retrieved from MD Anderson Tissue Banks.
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed
paraffin embedded (FFPE) sections. The primary antibodies
against TGF-bR2 (Novus Biologicals, LLC, Littleton, CO) and
SMAD4 (Proteintech Group, Inc. Chicago, IL) were used at 1:350
and 1:450 dilutions, respectively. The antibody complex was
detected using the ABC kit (Vector Laboratories, Burlingame,
CA). Nuclear and cytoplasm staining was recorded for both
markers. The staining intensity was scored as 0 for negative, 1 for
weak, 2 for intermediate, and 3 for strong staining. The percentage
of cells with positive staining were scored as 0 for none, 1 for 1–
50%, and 2 for .50%. The final staining score was the product of
the intensity and percentage scores. Each slide was evaluated by
two investigators (Drs. Dongfeng Tan and Yanan Li) and
consistent data from both evaluators were used in the final
statistical analysis.
Plasma Level of TGF-b1
Plasma level of TGF-b1 was measured by the Immune
Monitoring Core Laboratory of MD Anderson using the MSDH
96-Well MULTI-ARRAYHHuman TGF-b1 Assay kit (Meso Scale
Discovery, Rockville, MD). All samples were analyzed in duplicate
and each assay had a positive and a negative control. The variance
of the duplicate samples was less than 10%. All patients involved in
this assay were recruited to a case control study at MD Anderson
Cancer Center [16,17]. Blood samples were collected before the
cancer treatment or at the time of diagnosis in 95% of the cases.
Plasma samples had been stored at 280uC without thawing before
use in this assay.
Genotyping
DNA was extracted from peripheral lymphocytes in the
majority of the samples and from FFPE in 27 samples. Genotyping
used the Sequenom method as previously described [18]. A total of
28 SNPs of the TGF-b1, TGF-b2, TGF-b3, TGF-bR1, TGF-bR2
and SMAD4 genes were selected with a focus on potentially
functional SNPs, i.e. SNPs in the coding region (nonsynonymous
or synonymous), untranslated region (UTR), promoter region and
splicing sites, or ins/del and frame-shift SNPs. SNPs were
identified from the NCBI SNP database and SNP500 Cancer
database or via literature review and functional analysis using the
F-SNP software (http://compbio.cs.queensu.ca/F-SNP/). About
10% of the samples were analyzed in duplicate and inconsistent
data were excluded from the final statistical analysis.
Statistical Analysis
IHC score and plasma TGF-b1 levels were presented as mean
6 standard deviation. The mean difference between groups was
compared using the Student’s t-test. The associations of these
markers and OS were analyzed using Kaplan Meier plot, log-rank
Table 1. Characteristics of the patient population (n, %).
Variable IHC Plasma Genotyping
(n =91) (n =644) (n=1,636)
Age (years)
,50 14 (15.4) 98 (15.2) 218 (13.3)
51–60 28 (30.8) 184 (28.6) 459 (28.1)
61–70 37 (40.7) 237 (36.8) 597 (36.5)
.70 12 (13.2) 125 (19.74) 341 (20.8)
Race
White 71 (84.6) 629 (97.7) 1,429 (87.3)
Hispanic 1 (1.1) 4 (0.6) 87 (5.3)
Black 10 (11.0) 8 (1.2) 91 (5.6)
Others 3 (3.3) 2 (0.4) 29 (1.8)
Sex
Male 66 (72.5) 396 (61.5) 965 (59.0)
Female 25 (27.5) 248 (38.5) 671 (41.0)
Stage
Localized 8 (8.8) 162 (25.2) 533 (32.6)
Locally advanced 16 (17.6) 197 (30.6) 504 (30.8)
Metastatic 67 (73.6) 285 (44.3) 599 (36.6)
CA19-9 (Unit/mL)
,47 13 (14.3) 117 (18.2) 340 (20.8)
48–500 19 (20.9) 231 (35.9) 612 (37.4)
501–1000 11 (12.1) 60 (9.3) 158 (9.7)
.1000 34 (37.4) 207 (32.1) 435 (26.6)
Missing 14 (15.4) 29 (4.5) 91 (5.6)
doi:10.1371/journal.pone.0085942.t001
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test and Cox proportional hazards models with adjustment for sex,
race, age, tumor stage, and CA19-9 levels. These markers were
also analyzed as categorical variables using the median or quartiles
as cutoff values.
The distribution of genotypes was examined for Hardy-
Weinberg equilibrium with the goodness-of-fit chi-squared test.
Genotype and allele frequency of the SNPs were determined by
direct gene counting. The homozygous and heterozygous geno-
types were combined if the frequency of the homozygote was very
low or if both genotypes had the same trend of effect [e.g., shorter
overall survival (OS) compared with the referent group]. The
association between genotype and OS was estimated using the
Kaplan-Meier plot and log-rank test. Hazard ratios (HR) and 95%
confidence interval (CI) were estimated using the multivariate Cox
regression proportional hazards models. All statistical testing used
SPSS software (SPSS Inc, Chicago, IL). P value of ,0.05 was
considered statistically significant. False positive finding associated
with multiple testing was controlled by Bonfferoni correction.
Results
The study population was identified from a case-control study
on pancreatic cancer conducted at The University of Texas MD
Anderson Cancer Center from 1999 through 2012 [16,17]. Three
groups of patients were identified: 1) 120 patients had adequate
Figure 1. Typical Immunohistochemical staining pattern for TGF-bR2 and SMAD4 in pancreatic adenocarcinoma tumor tissues. A:
Positive nuclear expression of TGF-bR2 in a moderately differentiated ductal adenocarcinoma of the pancreas (Magnification: 10640). B: Positive
nuclear expression of SMAD4 in moderately differentiated ductal adenocarcinoma of the pancreas (Magnification: 10640).
doi:10.1371/journal.pone.0085942.g001
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biopsy or surgical samples for the immunohistochemistry; 2) 644
patients had blood samples collected for the plasma TGF-b1
measurement; and 3) 1636 patients had adequate DNA samples
available for genotyping. The demographic and clinical charac-
teristics of the three study populations are described in Table 1.
The age, gender and racial/ethnic distributions of the patients
were representative of the MD Anderson patient population. The
mean age is 60.6, 61.4 and 62.1 years for patients included in the
IHC, ELISA and genotyping study, respectively. Men consisted
72.5%, 61.5% and 59.0% of the three study populations. More
than 85% of the study subjects were non-Hispanic whites. Nearly
74% of the patients in IHC group had metastatic disease and
therefore the tissue samples used for IHC were mostly biopsy
samples [Stage II: 8 (8.8%); Stage III: 16 (17.6%); Stage IV: 67
(73.6%)]. Information on tumor grade was available in 60 samples
of which, 20 were moderately differentiated and 40 were poorly
differentiated tumors.
Protein Expression
A total of 91 samples were stained for TGF-bR2 and SMAD4.
Quantitative evaluation was achieved in 88 samples for TGF-bR2
and 81 samples for SMAD4 (Fig. 1). Nuclear and cytoplasm
staining was observed, respectively, in 81 (92%) and 87 (99%)
samples for TGF-bR2 and in 47 (58%) and 72 (89%) samples for
SMAD4 (Fig. 1). The overall IHC score for either marker was not
associated with OS (data not shown). Patients with a higher
nuclear staining score for TGF-bR2 had a relatively shorter OS
than those with a lower score (Median survival time [MST] 12.0
versus 8.6 months, Table 2), but this difference was not statistically
significant. Nuclear staining of SMAD4 was present more
frequently (16/20, 80%) in poorly differentiated tumors than in
moderately differentiated tumors (19/40, 47.5%) (P=0.016, x2
test). Furthermore, when TGF-bR2 and SMAD4 nuclear expres-
sion was analyzed in combination, we noted that patients with low
expression of TGF-bR2 and high expression of SMAD4 had a
significantly longer OS than others (Fig. 2), although this
difference was not statistically significant after adjusting for other
clinical predictors (Table 2).
Plasma TGF-b1 Level
Plasma level of TGF-b1 was measured in 644 patients. The
mean and median level of TGF-b1 was 15.44 (SD 10.99) and
12.61 (interquartile range: 8.31 to 19.04) ng/ml, respectively. The
level of TGF-b1 was relatively higher in patients with localized
tumor than those with advanced tumors. The mean 6 SD of
TGF-b1 level was 17.2614.3, 13.968.7 and 15.5610.0 ng/ml in
patients with localized, locally advanced and metastatic tumors,
respectively (P=0.02, ANOVA). However, the level of TGF-b1
was not associated with OS in patients with localized tumor
(Table 3) or in the entire study population (MST=12.9 and 11.1
months for those in the lower quartiles versus those in the upper
quartile range, P=0.78, log-rank test). However, patients with
locally advanced or metastatic disease and in the upper quartile
range of TGF-b1 level had significantly reduced survival than their
Figure 2. Overall survival of patients with various nuclear
expression levels of TGF-bR2 and SMAD4. Nuclear staining score
0–1 is defined as low for TGF-bR2 and a score 0 as low for SMAD4. Red
line: TGF-bR2 is high and SMAD4 is low (HL); black line: both high (HH);
green line: both are low (LL); purple line: TGF-bR2 is low and SMAD4 is
high (LH). The median survival times are 7.8, 8.6, 11.3, and 15.6 months
for the HL, HH, LL and LH groups, respectively. Log-rank test P values
and results of Cox regression analysis are presented in Table 2. Thus,
TGFb-R2/SMAD4 ratio may be prognostic, with low values correspond-
ing with an improved survival.
doi:10.1371/journal.pone.0085942.g002
Table 2. Nuclear staining for TGF-bR2 and SMAD4 and association with overall survival.
Marker No. of Patients No. of DeathMST (months) P log-rank HR (95% CI) P value
TGF-bR2
Low (score 0–1) 24 21 12.0 1.0
High (score 2) 64 51 8.6 0.135 1.54 (0.88–2.68) 0.131
SMAD4
Low (score 0) 34 32 9.1 1.0
High (score 1–2) 47 40 9.3 0.223 0.84 (0.51–1.37) 0.480
TGF-bR2 SMAD4
High Low 21 21 7.8 1.0
High High 36 30 8.6 0.767 0.66 (0.31–1.41) 0.818
Low Low 13 11 11.3 0.532 0.76 (0.38–1.52) 0.939
Low High 8 8 15.6 0.007 0.40 (0.15–1.06) 0.062
MST: median survival time; HR: hazard ratio; CI: confidence interval.
HR was adjusted for age, sex, race, stage and CA19-9.
doi:10.1371/journal.pone.0085942.t002
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counterparts (Table 3). TGF-b1 remained as a significant
predictor in a Cox regression model with adjustment for
demographics and other clinical factors.
Genotyping
Genotyping was performed in 1636 patients. The reported
minor allele frequency and potential functional significance of the
Table 3. Plasma TGF-b1 level and overall survival.
Patients TGF-b1 (ng/ml) No. of Patients No. of Deaths MST (months) P value (log-rank) HR (95% CI) P value
Localized 0.632 0.548
,19.05 109 78 26.43 1.0
$19.05 53 35 27.66 0.88 (0.58–1.33)
Locally advanced & metastatic 0.006 0.011
,19.05 375 308 10.67 1.0
$19.05 107 101 7.97 1.35 (1.07–1.69)
19.05 is the 25th percentile of the TGF-b1 value of the entire study population.
HR was adjusted for age, sex, race, stage and CA19-9.
doi:10.1371/journal.pone.0085942.t003
Figure 3. Plot of overall survival curve in patients with all patients (A), patients with localized (B), locally advanced (C) or metastatic
tumors by SMAD4 SNP rs2704733 genotype. Blue line: AA genotype; green line: AG/GG genotype. AA genotype was associated with an
improved survival in the entire study population. On subgroup analysis, this survival difference was more relevant for advanced disease stage. P
values by log-rank test are ,0.0001, 0.369, 0.007, and 0.031 for panels A, B, C and D, respectively.
doi:10.1371/journal.pone.0085942.g003
TGF-Beta Pathway in Pancreatic Cancer
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28 tested SNPs is described in Table 4. No variant allele was
detected for nine SNPs. Among the six common SNPs with minor
allele frequency greater than 5%, three followed the Hardy
Weinberg Equilibrium (HWE) and three deviated from the HWE
(Table 2). The genotype distribution and overall survival time by
genotype of the 19 informative SNPs are presented in Table 5. A
significant association of SMAD4 SNP rs113545983 with OS was
observed (Panel A, Fig. 3), and the association was stronger in
patients with advanced disease (Panels C and D, Fig. 3) than those
with localized disease (Panel B, Fig. 3). The mutant G allele of
SNP rs113545983 remained as a significant predictor for death in
Cox regression model after adjusting for stage and resection status
among all patients (HR: 1.54, 95% CI: 1.21–1.96, P,0.001). No
other SNPs showed significant association with OS. TGF-bR2
SNP rs2248048 had a weak association with OS without statistical
significance (P=0.09, log rank test).
Table 4. MAF and functional significance of the SNPs
investigated in the current study.
Gene SNP ID Allele Functional MAF
TGF-b1 rs35383147 A/G/T ThR24 = NA
TGF-b2 rs6684205 G/A intron 0.482
rs114663618* C/T intron NA
rs10482810 G/C Val235Leu 0.001
rs7531245 A/C intron 0.011
TGF-b3 rs11466415 C/T Ala13 = 0.002
rs4252315 C/T Thr60Met 0.003
TGF-bR1 rs11466445* 2/GGCGGCGGC Ala23fs NA
rs75857126* C/T Ile147Thr NA
rs113982335* A/C Asn160His NA
TGF-bR2 rs2043136 T/C 39 near gene 0.314
rs1155705 A/G intron 0.425
rs3087465 A/G/T 59 near gene 0.337
rs11466530* C/T intron 0.001
rs17026332 A/C 39 UTR 0.009
rs11466512 A/T intron 0.311
rs61762550* C/T Arg218Trp 0.0005
rs114457508 T/G Val276Gly NA
rs28934568* C/T Leu333Pro NA
rs34833812 C/T Thr340Met 0.006
rs3209742* A/T Glu341Val NA
rs17854016 G/T Glu360Ter NA
rs2228048 C/T Asn41= 0.083
SMAD4 rs4939650 C/G 59 near gene 0.497
rs1801250 C/T Phe362 = 0.002
rs112891188* C/T Ala220 = NA
rs75667697 G/T Leu229Arg NA
rs113545983 A/G Gln549 = NA
MAF: minor allele frequency.
*No variant allele was detected in the current study population.
‘‘ = ’’ represents synonymous gene variants, i.e. no amino acid change.
doi:10.1371/journal.pone.0085942.t004
Table 5. Genotype frequency and median survival time.
Gene RS# Genotype N MST P
TGF-b1 rs35383147 G 1618 14.6 0.26
GT/T (8/1) 9 14.6
TGF-b2 rs6684205 A 557 15.1 0.9
AG 858 14.6
G 155 14.9
rs10482810 G 1618 14.6 0.24
GC 18 14.8
rs7531245 A 1561 14.7 0.61
AC 14 16.1
TGF-b3 rs11466415 C 1589 14.7 0.59
CT 47 12.8
rs4252315 C 1629 14.6 0.37
CT 2 5.5
TGF-bR2 rs1155705 A 751 14.9 0.9
AG 723 14.4
G 159 13.9
rs2043136* T 876 14.9 0.82
TC 605 14.5
C 122 14.1
rs3087465* G 929 14.5 0.96
GA 592 14.8
A 103 14.3
rs11466512* T 802 15 0.4
AT 702 13.9
A 129 14.7
rs114457508 T 1629 14.7 0.34
TG 3 7.8
rs34833812 C 1565 14.8 0.09
TC/T (3/1) 4 22.5
rs17854016 G 1631 14.7 0.97
GT 1 20.4
rs2228048 C 1572 14.6 0.09
CT/T (56/2) 58 17.6
rs17026332 C 1557 14.7 0.62
CA/A 47 19.1
SMAD4 rs4939650 C 519 15.1 0.95
CG 847 14.4
G 260 14.6
rs1801250 T 1621 14.7 0.73
CT/C (3/1) 4 6.4
rs75667697 T 1631 14.7 0.28
GT 3 10.5
rs113545983 A 1543 14.8 ,.0001
AG 55 10.2
G 24 10.7
*SNPs that are conformed in HWE.
doi:10.1371/journal.pone.0085942.t005
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Discussion
Our goal in the current study was to investigate biomarkers in
the TGF-b pathway that could have prognostic value and
potentially predictive value for targeted therapy with inhibitors.
We interrogated the tumor biorepository at MD Anderson Cancer
Center and examined archival material including DNA, plasma
and tumor tissue samples for SNPs, TGF-b1 plasma level and
protein expression of TGF-bR2 and SMAD4. We observed that
patients with low expression of TGF-bR2 and high expression of
SMAD4 in their tumors had a significantly longer OS than other
subgroups in our study. We also noticed that patients with
advanced disease and high TGF-b1 plasma level had significantly
reduced survival than those with a lower level of TGF-b1. Finally,
we detected a significant association of SMAD4 SNP rs113545983
with patient survival. These observations provide valuable baseline
information regarding the TGF-b signaling pathway in pancreatic
cancer, which can be utilized in future targeted therapy clinical
trials. The TGF-b signaling pathway includes the ligands and the
receptors; and the ligand-receptor interactions lead to signal
transduction via SMADs. Previous IHC analysis has shown the
presence of ligand TGF-b1, TGF-b2 and TGF-b3 in PDAC
cancer cells and the presence of TGF-b2 was associated with
advanced tumor stage [19]. TGF-bR2 mRNA was expressed in
the majority of cancer cells and enhanced levels of TGF-bR2 has
been suggested to have a role in regulating human pancreatic
cancer cell growth [20]. TGF-b2R and SMAD4 gene was mutated
in 4% and 50% of the human PDAC, respectively [21]. Lack of
SMAD4 expression in the tumor has been associated with more
aggressive disease [22]. There are very limited data investigating
the prognostic value of TGF-b pathway proteins in advanced
pancreatic cancer patients. Although we did not find a significant
correlation between SMAD4 and TGF-bR2 expression individu-
ally with prognosis, we observed that TGF-b2R and SMAD4
protein expression was detected in 81% and 47% of the tumors
and patients with low expression of TGF-bR2 and high expression
of SMAD4 had a significantly longer OS than other subgroups in
our study. Hua et al, reported similar findings in a smaller
retrospective study of patients with advanced pancreatic cancer
[23]. A prior study from our institution suggested that SMAD4 loss
correlates with an adverse outcome in patients with locally
advanced pancreatic cancer receiving gemcitabine, oxaliplatin and
cetuximab [24]. As mentioned earlier, SMAD4 loss was associated
with disease dissemination in locally advanced and metastatic
pancreatic cancer cases by Iacobuzio-Donahue, et al in an autopsy
series [10]. On the other hand, a literature-based meta-analysis of
biomarkers in operated pancreatic cancer did not support the
prognostic value of SMAD4 in surgically resectable disease [25].
These findings are consistent with a stage-dependent role of the
TGF-b pathway.
Furthermore, we found that patients with advanced disease and
high TGF-b1 plasma level had significantly reduced survival than
those with a lower TGF-b1 level. This association was not seen in
patients with localized disease. A previous study has shown that
lack of TGF-b1 expression in tumor tissues was associated with
increased postoperative survival [19]. The reason for the
association between high TGF-b1 plasma level and poor survival
at advanced disease stage (and not with early stage disease) is
unclear. However, these results are consistent with preclinical data
that suggest that loss of the growth inhibitory response to TGF-b
signaling varies directly with the malignant stage of the tumor and
the more aggressive forms actually switch to autocrine and/or
paracrine growth stimulated by TGF-b. Tumors can also secrete
TGF-b1 leading to altered anti-tumor immunity [26,27]. To our
knowledge, there are no prior data investigating the prognostic
role of TGF-b1 plasma level in pancreatic cancer. Prior studies in
breast, prostate, esophageal and bladder cancer indicate a
correlation between high TGF-b1 plasma level and poor prognosis
[28–31]. Consistency with these reports and the relatively large
sample size of our study adds to the strength of our findings.
Because of the challenges in accessing the target tissues in patients
with advanced disease, plasma biomarkers for the TGF-b1
pathway may have a greater clinical value.
Genetic variations of the TGF-b pathway have been linked to
prognosis and survival in lung cancer by another study conducted
at our institution. In patients receiving platinum-based chemo-
therapy; BMP2:rs235756 and SMAD3:rs4776342 were signifi-
cantly associated with survival [15]. There are however, no studies
in pancreatic cancer correlating genomic variations of this
pathway with prognosis. We noted a significant association
between SMAD4 SNP rs113545983, a synonymous SNP, with
OS in this study. Patients carrying the variant allele had
significantly shorter OS and increased risk of death after adjusting
for other clinical predictors. This SNP is a synonymous SNP that
does not produce altered coding sequences and amino acid
substitution. However, a previous study has demonstrated that a
synonymous SNP could result in a protein product with altered
drug and inhibitor interactions [32]. Thus, the functional
consequence by this SNP needs to be investigated. It is also
possible that this SNP is in linkage disequilibrium with other
functional SNPs of this gene or some important genes in this
chromosome location. Further investigations will help to deter-
mine how this SNP is functionally associated with the SMAD4
signaling transduction and survival in pancreatic cancer patients.
The study has several limitations. Because of the limitation of
tissue samples and the low MAF SNP selected in the study, we
could not examine the correlation between genotypes, plasma
marker level and tissue markers. We only measured a few selected
markers from the many molecules that are involved in this
complex signaling pathway. Nevertheless, our data provide
valuable baseline information regarding this pathway expression
in pancreatic cancer, which can be utilized in targeted therapy
clinical trials. Based on the above findings, it can be hypothesized
that detection of high TGF-b1 plasma level, SMAD4SNP
rs113545983 or high TGF-bR2/SMAD4 tumor protein expres-
sion ratio may suggest a dependence on this pathway in patients
with advanced pancreatic cancer and this subset may potentially
benefit from TGF-b-targeted therapy.
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